Intensive Phase of Therapy of Tuberculosis and HIV Co-infection: CD4, CD8, and Certain Hematological Finding Amongst Patients in Yaounde Cameroon
International Journal of Immunology
Volume 3, Issue 6, December 2015, Pages: 72-77
Received: Nov. 13, 2015; Accepted: Nov. 24, 2015; Published: Dec. 14, 2015
Views 3851      Downloads 117
Authors
Guiedem Elise, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon; Center for the Study and Control of Communicable Diseases (CSCCD), Yaounde, Cameroon
Pefura Yone Eric Walter, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon; Pneumological Service, Yaounde Jamot Hospital, Yaounde, Cameroon
Ikomey George, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon; Center for the Study and Control of Communicable Diseases (CSCCD), Yaounde, Cameroon
Gonsu Kamga Hortense, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon
Monamele Chavely Gwladys, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon
Fokam Joseph, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon
Mesembe Martha, Center for the Study and Control of Communicable Diseases (CSCCD), Yaounde, Cameroon
Afane Ze Emmanuel, Pneumological Service, Yaounde Jamot Hospital, Yaounde, Cameroon
Okomo Assoumou Marie Claire, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon; Center for the Study and Control of Communicable Diseases (CSCCD), Yaounde, Cameroon
Article Tools
Follow on us
Abstract
Tuberculosis (TB) is an infectious disease which could cause depressive phenomena like those observed in Human Immunodeficiency Virus (HIV). Our study aimed at evaluating the changes of T-cells and certain blood parameters during intensive phase of TB treatment. In this prospective cohort, 140 consenting tuberculosis patients were enrolled. 5ml of blood was collected at baseline (M0), after one month (M1) and after two months (M2). Enumeration of CD4 cells, CD8 cells, and hematological parameters were done following standard protocols.The 118 participants comprised 63 (53.4%) TB/HIV negative patients (group 1) and 55 (46.6%) TB/HIV positive patients (group 2). At M0, blood levels of CD4, hemoglobin, total lymphocytes and platelets in group 2 were significantly lower than those of group 1 with p values of 0.001, 0.002, 0.018 and 0.032 respectively. CD8 level was significantly low in group 1 as compared to group 2 (p value: 0.38). Monocytes were low in both groups with no significant difference (p value: 0.097). At M2, there was a significant increase in the levels of CD4, CD8, monocytes, and hemoglobin as compared to M0. There was no significant change on level of total lymphocytes and platelets. In group 2: At M2, there was a significant increase in the levels of CD4, monocytes, hemoglobin, and platelets, and no statistically significant change on levels of CD8 cells and total lymphocytes. TB infection may result in lymphopenia, monopenia, and anemia, while co-infection with HIV may add thrombopenia to the mentioned disorders.
Keywords
Anemia, HIV, Lymphopenia, Monopenia, Thrombopenia, Treatment, Tuberculosis
To cite this article
Guiedem Elise, Pefura Yone Eric Walter, Ikomey George, Gonsu Kamga Hortense, Monamele Chavely Gwladys, Fokam Joseph, Mesembe Martha, Afane Ze Emmanuel, Okomo Assoumou Marie Claire, Intensive Phase of Therapy of Tuberculosis and HIV Co-infection: CD4, CD8, and Certain Hematological Finding Amongst Patients in Yaounde Cameroon, International Journal of Immunology. Vol. 3, No. 6, 2015, pp. 72-77. doi: 10.11648/j.iji.20150306.12
Copyright
Copyright © 2015 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
WHO. Global tuberculosis report, 2013.
[2]
WHO. Global Report. UNAIDS report on the global AIDS epidemic, 2013.
[3]
Kuaban C., Pefura E, Bava D, Onana I. Early mortality in new patients on treatment for smear positive pulmonary tuberculosis in Yaounde-Cameroon. Health Sci. Dis: (December 2011). Vol 12 (4).
[4]
Mvondo D. La nutrition, traitement adjuvant du syndrome d’immunodéficience acquise (SIDA), 2000. www.supersmart.com/nutranews
[5]
Dagara A.Y., Adjih K., Tchaptchet Heunda S. Prévalence de la co-infection VIH-tuberculose et impact de l'évolution VIH sur la tuberculose pulmonaire au Togo. Bull. Soc. Pathol. Exot., 2011,104, 342-346.
[6]
Aït-Khaled N, Enarson D. Tuberculose Manuel pour les Etudiants en Medecine. Who/CDS/TB/99.272.
[7]
Afane Ze E. , Guiedem E., Okomo Assoumou MC, Pefura Yone EW. Impact Dépressif de l’Infection Tuberculeuse sur les Cellules Immunitaires de Défense. 2013; Health Sci. Dis: Vol 14 (2).
[8]
Semba RD, Tang AM. Micronutrients and the Pathogenesis of Human Immunodeficiency Virus Infection., Br J Nutr, 1999; 81: 181-189.
[9]
Aska A., Anazi A., Subaei A., Hedaithy M. CD4+ T-lymphopenia in HIV negative tuberculous patients at King Khalid University Hospital in Riyadh, Saudi Arabia. 2011, jun 21 16(6): 285-8.
[10]
Aubry P. La tuberculose à l’heure du SIDA, actualités. 2011; Medecinetropicale.free.fr/cours/tuberculose-sida.pdf
[11]
Coussens K., Wilkinson J., Vladyslav N, Elkington T., Yasmeen H, Kamrul I, Peter M., Graham H. B., Alleyna P., Geoffrey E., Mathina D, Heather J., Baker V,. Barker D., Drobniewski A., Mein A., Leena B., Nuamah A., Griffiths J., Martineau R. Ethnic Variation in Inflammatory Profile in Tuberculosis. Published. 2013; DOI: 10.1371/journal. ppat. 1003468.
[12]
Davoudi Rasoolinegad M, younesian M, Hajiabdolbaghi M, soudbakhsh a, Jafari s, Emadikouchak H, Mehrpouya M, Lotfi H. CD4+ cell counts in patients with different clinical manifestations of tuberculosis. 2008; Braz J Infect Dis; 12: 483-6.
[13]
Aït-Khaled N, Alarcón E, Armengol R: Prise en charge de la tuberculose. Guide des éléments essentiels pour une bonne pratique. (Sixième édition). Union Internationale Contre la Tuberculose et les Maladies Respiratorires. 2010.
[14]
Uppal S. Tewari C., Verma S., Dhot P. Comparison of CD4 and CD8 Lymphocyte Counts in HIV-negative Pulmonary Tb Patients with Those in normal blood Donors and the Effect of antitubercular Treatment: Hospitalbased Flow Cytometric study. Cytometry Part b (Clinical Cytometry). 2004; 61b: 20-6.
[15]
Bonaparte M.I., Barker E., killing of human immunodeficiency virus infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood. 2004; 104: 2087-2094.
[16]
Afane Ze A, Bitchong C E, Pefura Y E. Co-infection tuberculose et VIH: hausse des CD4 avec le traitement par antituberculeux seuls. Revue de médecine et de pharmacie N°1 2011: P 75-82.
[17]
Dinh A., Perronne C. Aspects cliniques et thérapeutiques de la tuberculose chez l’adulte et l’enfant. EMC-Maladies infectieuses. 2013; 10(4): 1-11[article 8-038-C-30].
[18]
Dhruv S., Carolyn Bigbee, JoAnne L. Flynn and Denise E. contribution of CD8+ T Cells to Control of Mycobacterium tuberculosis Infection. J Immunol 2006; 176:4296-4314.
[19]
Leclercq p., Roudière L., Viard J.P. severe complicatins of antiretroviral treatments. Reanimation 13. 2004, 238-248.
[20]
Stephen H.-F. M. Elliott W., Coleman M., Dorris E. R., Parthiban N., Wui-Mei Chew, McLaughlin A.M., Keane J. Networked T Cell Death following Macrophage Infection by Mycobacterium tuberculosis. PLoS One. 2012; 7(6): e38488.
[21]
Lang P.A., Lang K.S., Xu H.C., (2011). Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Academie des Sciences USA.
[22]
Joshua S. Woodworth, Ying Wu and Samuel M. Behar. Mycobacterium tuberculosis-Specific CD8_ T Cells Require Perforin to Kill Target Cells and Provide Protection In Vivo. J Immunol 2008; 181:8595-8603.
[23]
Sarah M. Alejandra S. Mycobacterium tuberculosis Inhibits Macrophage Responses to IFN- ɣ through Myeloid Differentiation Factor 88-Dependent and –Independent Mechanisms. J. Immunol. 2004 172:6272-6280.
[24]
Pharmaetudes. antirétroviraux; version 2,5. de www.pharmaetude.com de www.pharmaetude.com
[25]
Khalid S., Mustapha M., Ibrahim H., Andes E. Cytopenie et virus d’immunodeficience humaine. Doi: 10 1684/met 2011, 17 (3) 183-195.
[26]
Török M.E., Farrar J.J. When to start antiretroviral therapy in HIV-associated tuberculosis. N. Engl. J. Med., 2011, 365, 1538-1540.
[27]
Kawai K., Villamor E., Mugusi F., Saathoff E., Urassa W., Bosch R., Spiegelman D., Predictors of change in nutritional and hemoglobin status among adults treated for tuberculosis in Tanzania. 2011; 15(10): 1380–1389.
[28]
Yonghong F., Hongyun Y., Guangliang M., Mao L, Yue J, Xiao H, Zhongyi H. Elevated Serum Levels of CCL17 Correlate with Increased Peripheral Blood Platelet Count in Patients with Active Tuberculosis in China. 2011; 18(4): 629–632.
[29]
Nardi MA, Li Z, Karpatkin S. HIV-1-related thrombocytopenia. In: Platelets (Second Edition): 847-59.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186